N Giannoukakis

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Cellular environment and freedom of gene expression
    Massimo Pietropaolo
    Nat Immunol 3:335; author reply 336. 2002
  2. ncbi request reprint DiaPep277 (DeveloGen)
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Diabetes Institute, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 6:1043-50. 2005
  3. ncbi request reprint Evaluation of ranirestat for the treatment of diabetic neuropathy
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Children s Hospital of Pittsburgh, Department of Pathology and Immunology, 4401 Penn Avenue, Pittsburgh, PA 15224, USA 1 412 692 8127 voice 1 412 692 7515
    Expert Opin Drug Metab Toxicol 10:1051-9. 2014
  4. pmc Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?
    Brett Phillips
    Division of Immunogenetics, Department of Pediatrics, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
    Clin Dev Immunol 2011:432016. 2011
  5. pmc Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice
    Valentina Di Caro
    Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America RiMed Foundation, Palermo, Italy
    PLoS ONE 9:e83575. 2014
  6. doi request reprint Interview: Immunoregulatory dendritic cells to treat autoimmunity are ready for the clinic
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Rangos Research Center 6123, 4401 Penn Avenue, PA, USA
    Immunotherapy 5:919-21. 2013
  7. doi request reprint Tolerogenic dendritic cells for Type 1 diabetes
    Nick Giannoukakis
    Department of Pathology, University of Pittsburgh School of Medicine, Children s Hospital of Pittsburgh, Pittsburgh, PA 15224, USA
    Immunotherapy 5:569-71. 2013
  8. ncbi request reprint Pyridoxamine (BioStratum)
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 6:410-8. 2005
  9. ncbi request reprint Gene therapy for type 1 diabetes: a proposal to move to the next level
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Department of Pathology, Pittsburgh, PA 15261, USA
    Curr Opin Mol Ther 7:467-75. 2005
  10. ncbi request reprint Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Department of Pathology and Immunology, Diabetes Institute, Rangos Research Center, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Expert Opin Investig Drugs 17:575-81. 2008

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Cellular environment and freedom of gene expression
    Massimo Pietropaolo
    Nat Immunol 3:335; author reply 336. 2002
  2. ncbi request reprint DiaPep277 (DeveloGen)
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Diabetes Institute, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 6:1043-50. 2005
    ....
  3. ncbi request reprint Evaluation of ranirestat for the treatment of diabetic neuropathy
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Children s Hospital of Pittsburgh, Department of Pathology and Immunology, 4401 Penn Avenue, Pittsburgh, PA 15224, USA 1 412 692 8127 voice 1 412 692 7515
    Expert Opin Drug Metab Toxicol 10:1051-9. 2014
    ..The objective of this evaluation is to summarize and provide expert opinion on the status of ranirestat with an emphasis on its pharmacokinetics in the context of its potential effects to prevent/treat diabetic complications...
  4. pmc Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?
    Brett Phillips
    Division of Immunogenetics, Department of Pediatrics, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA 15224, USA
    Clin Dev Immunol 2011:432016. 2011
    ....
  5. pmc Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice
    Valentina Di Caro
    Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America RiMed Foundation, Palermo, Italy
    PLoS ONE 9:e83575. 2014
    ....
  6. doi request reprint Interview: Immunoregulatory dendritic cells to treat autoimmunity are ready for the clinic
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Rangos Research Center 6123, 4401 Penn Avenue, PA, USA
    Immunotherapy 5:919-21. 2013
    ..He has mentored graduate, MD/PhD students, as well as clinical fellows. Giannoukakis is also one of the founders of DiaVacs(®) (NJ, USA), a biotechnology entity leveraging dendritic cell therapy for autoimmunity. ..
  7. doi request reprint Tolerogenic dendritic cells for Type 1 diabetes
    Nick Giannoukakis
    Department of Pathology, University of Pittsburgh School of Medicine, Children s Hospital of Pittsburgh, Pittsburgh, PA 15224, USA
    Immunotherapy 5:569-71. 2013
    ..Based on this analysis, the importance of quality control testing DCs to ensure that their tolerogenic character is stable in vitro and in vivo is highlighted...
  8. ncbi request reprint Pyridoxamine (BioStratum)
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 6:410-8. 2005
    ..BioStratum is developing pyridoxamine (Pyridorin), an advanced glycation end-product (AGE) inhibitor, for the potential prevention of diabetic nephropathy. By January 2004, phase II trials had been completed...
  9. ncbi request reprint Gene therapy for type 1 diabetes: a proposal to move to the next level
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Department of Pathology, Pittsburgh, PA 15261, USA
    Curr Opin Mol Ther 7:467-75. 2005
    ..Additionally, newer emerging technologies that can, in the future, complement those that are currently readily adaptable to clinical implementation are suggested...
  10. ncbi request reprint Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Department of Pathology and Immunology, Diabetes Institute, Rangos Research Center, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Expert Opin Investig Drugs 17:575-81. 2008
    ..The involvement of the sorbitol pathway in complications has provided mechanistic insights into the biochemistry of complications and the key enzyme, aldose reductase, has become an attractive pharmacologic target...
  11. ncbi request reprint Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 7:916-23. 2006
    ..Phase III trials were ongoing in February 2006...
  12. ncbi request reprint CJC-1131. ConjuChem
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 4:1245-9. 2003
    ..In August 2003, a phase I/II trial was completed and a phase II trial was expected to begin in October...
  13. ncbi request reprint Fidarestat. Sanwa Kagaku/NC Curex/Sankyo
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 4:1233-9. 2003
    ..Fidarestat is an aldose reductase inhibitor being co-developed by Sanwa Kagaku, NC Curex (a joint venture company created by Japan Energy and Kaken) and Sankyo, for the potential treatment of diabetic neuropathy...
  14. ncbi request reprint Genes and engineered cells as drugs for type I and type II diabetes mellitus therapy and prevention
    Nick Giannoukakis
    Department of Pathology, University of Pittsburgh School of Medicine, PA 15213, USA
    Curr Opin Investig Drugs 3:735-51. 2002
    ..In this review, we attempt to illustrate pivotal studies demonstrating the suitability of genes and cells as drugs in type 1 and type 2 diabetes mellitus, and also provide some other targets that may be suitable for clinical utility...
  15. ncbi request reprint Gene and cell therapies for diabetes mellitus: strategies and clinical potential
    Nick Giannoukakis
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    BioDrugs 16:149-73. 2002
    ..In the end, progress in vector design, elucidation of antigen-specific immunity and insulin sensitivity will provide the framework for gene drug use in the treatment of type 1 and type 2 diabetes...
  16. ncbi request reprint Therapeutic strategies for Type 1 and Type 2 diabetes mellitus
    N Giannoukakis
    Dept of Pathology, and Diabetes Institute, University of Pittsburgh School of Medicine, Rangos Research Center, PA 15213, USA
    Diabetes Nutr Metab 15:173-203. 2002
    ..Herein, we present an overview of the current status of drug, gene and cell therapy for T1DM and T2DM and we propose novel therapeutic options that could be clinically useful...
  17. ncbi request reprint BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Diabetes Institute, Rangos Research Center, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 8:842-8. 2007
    ..Phase II clinical trials are underway, including a phase II trial evaluating a slow release formulation...
  18. ncbi request reprint Exenatide. Amylin/Eli Lilly
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Curr Opin Investig Drugs 4:459-65. 2003
    ..In January 2002 the second phase III trial, of exenatide in conjunction with sulfonylureas, was initiated and in March 2002, Amylin initiated the third phase III trial, of exenatide in combination with metformin and sulfonylureas...
  19. pmc Retinoic acid-producing, ex-vivo-generated human tolerogenic dendritic cells induce the proliferation of immunosuppressive B lymphocytes
    V Di Caro
    Department of Pediatrics, Division of Immunogenetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA RiMED Foundation, Palermo, Italy
    Clin Exp Immunol 174:302-17. 2013
    ....
  20. ncbi request reprint Prolongation of islet allograft survival following ex vivo transduction with adenovirus encoding a soluble type 1 TNF receptor-Ig fusion decoy
    J Machen
    Diabetes Institute, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Gene Ther 11:1506-14. 2004
    ..These data support the potential utility of TNFR-Ig gene transfer to islets as a means of facilitating allogeneic islet transplantation...
  21. ncbi request reprint Gene- and cell-based therapeutics for type I diabetes mellitus
    R Bottino
    Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Gene Ther 10:875-89. 2003
    ..An assessment of the current state of the science and potential leads to the conclusion that some strategies are ready for safety trials while others require varying degrees of technical and conceptual refinement...
  22. ncbi request reprint Current status and prospects for gene and cell therapeutics for type 1 diabetes mellitus
    Nick Giannoukakis
    Department of Pathology and Diabetes Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Rev Endocr Metab Disord 4:369-80. 2003
  23. ncbi request reprint Dendritic cell-based therapy in Type 1 diabetes mellitus
    Brett Phillips
    University of Pittsburgh School of Medicine, Department of Pediatrics, Division of Immunogenetics, Children s Hospital of Pittsburgh, Rangos Research Center, 530 45th Street, Pittsburgh, PA 15201, USA
    Expert Rev Clin Immunol 5:325-39. 2009
    ....
  24. ncbi request reprint Gene therapy for type 1 diabetes: is it ready for the clinic?
    Antonella D'Anneo
    Diabetes Institute, Children s Hospital of Pittsburgh, Pittsburgh 15213, USA
    Immunol Res 36:83-9. 2006
    ..A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner...
  25. ncbi request reprint Gene therapy technology applied to disorders of glucose metabolism: promise, achievements, and prospects
    Nick Giannoukakis
    University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Biotechniques 35:122-45. 2003
    ..Current efforts aimed at assessing the future of gene therapy for diabetes must, at the very least, take into account the importance of moving successful methods into human safety trials...
  26. ncbi request reprint Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes
    A N Balamurugan
    Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Pancreas 32:231-43. 2006
    ..All together, islet cell transplantation is moving forward...
  27. pmc FoxO1 links insulin resistance to proinflammatory cytokine IL-1beta production in macrophages
    Dongming Su
    Division of Immunogenetics, Department of Pediatrics, Children s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Diabetes 58:2624-33. 2009
    ..Our goal is to decipher the molecular linkage between proinflammatory cytokine production and insulin resistance in macrophages...
  28. ncbi request reprint Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activity
    Linlin Ma
    Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Diabetes 52:1976-85. 2003
    ..These findings provide novel insights into the mechanisms of autoimmune diabetes and may lead to development of novel preventive strategies...
  29. ncbi request reprint Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyond
    Nick Giannoukakis
    Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Pediatr Diabetes 9:4-13. 2008
    ..Herein, we outline the current status of non-insulin-based therapies for T1D, with a focus on cell-based immunomodulation which we propose can achieve all three criteria illustrated above...
  30. ncbi request reprint Gene therapy for type 1 diabetes
    Nick Giannoukakis
    Diabetes Institute, Pediatric Research Section, Children s Hospital of Pittsburgh and University of Pittsburgh, Rangos Research Center, Pittsburgh, PA 15213, USA
    Am J Ther 12:512-28. 2005
    ..Despite the early successes in a number of animal models, the true test of efficacy in humans remains to be demonstrated...
  31. pmc Interleukin-7 matures suppressive CD127(+) forkhead box P3 (FoxP3)(+) T cells into CD127(-) CD25(high) FoxP3(+) regulatory T cells
    V Di Caro
    Department of Pediatrics, Division of Immunogenetics, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, PA 15224, USA
    Clin Exp Immunol 165:60-76. 2011
    ....
  32. ncbi request reprint Gene therapy strategies to prevent autoimmune disorders
    Massimo Trucco
    Department of Pediatrics, Division of Immunogenetics, Children s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Curr Gene Ther 2:341-54. 2002
    ..The potential utility of gene therapy strategies promoting tolerance in two model autoimmune disorders, type I diabetes mellitus and rheumatoid arthritis are discussed in this review...
  33. ncbi request reprint Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitus
    Massimo Trucco
    Children s Hospital of Pittsburgh, Diabetes Institute, Pittsburgh, PA 15213, USA
    Expert Opin Biol Ther 7:951-63. 2007
    ....
  34. doi request reprint Renal diseases as targets of gene therapy
    Brett Phillips
    Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Contrib Nephrol 159:1-12. 2008
    ..While continued research and clinical trials are needed to identify a robust system of gene delivery, gene therapy techniques have great potential to treat kidney disease at the cellular level and improve patient quality of life...
  35. ncbi request reprint Induction of immune tolerance to facilitate beta cell regeneration in type 1 diabetes
    Lorenzo Pasquali
    Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Adv Drug Deliv Rev 60:106-13. 2008
    ..Given that these outcomes have already been confirmed in humans, refinement of existing protocols along with novel methods adapted to T1DM reversal will allow translation into clinical trials...
  36. ncbi request reprint Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells
    Jo Harnaha
    Department of Pathology, University of Pittsburgh School of Medicine, Diabetes Institute, Rangos Research Center, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA
    Diabetes 55:158-70. 2006
    ....
  37. ncbi request reprint Dendritic cell mediated therapy for immunoregulation of type 1 diabetes mellitus
    Brett E Phillips
    Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, PA, USA
    Pediatr Endocrinol Rev 5:873-9. 2008
    ..Here we will focus on immunoregulatory techniques to prevent beta cell loss due to the autoimmunity found in type 1 diabetes mellitus...
  38. ncbi request reprint Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells
    Jennifer Machen
    Diabetes Institute, Department of Pediatrics, University of Pittsburgh School of Medicine, PA 15213, USA
    J Immunol 173:4331-41. 2004
    ..This approach is a useful tool by which DC-mediated activation of regulatory T cells can be studied as well as a potential therapeutic option for type 1 diabetes...
  39. pmc A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes
    Brett Phillips
    Diabetes Institute, Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Diabetes 57:1544-55. 2008
    ..This study was aimed at ascertaining the efficacy of antisense oligonucleotide-formulated microspheres to prevent type 1 diabetes and to reverse new-onset disease...